CXBS — Corix Bioscience Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.31m
- $0.69m
Annual income statement for Corix Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2012 January 31st | 2013 January 31st | 2014 January 31st | 2015 January 31st | 2016 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.694 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.076 | 1.7 | 1.72 | 0.054 | 4.66 |
Operating Profit | -0.076 | -1.7 | -1.72 | -0.054 | -3.97 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.076 | -1.7 | -1.72 | -0.057 | -4.43 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,016 | -20,580 | -90 | -0.367 | -0.497 |
Dividends per Share |